NRBO — Neurobo Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $17.71m
- -$4.72m
- 28
- 31
- 52
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.06 | ||
| Price to Tang. Book | 1.06 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -94.44% | ||
| Return on Equity | -64.89% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused primarily on therapies for cardiometabolic diseases. Its therapeutics programs include DA-1241 and DA-1726. DA-1241 is a novel G-Protein-Coupled Receptor 119 agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucose metabolism, lipid metabolism and weight loss. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a glucagon-like peptide-1 receptor and glucagon receptor dual agonist. OXM is a naturally occurring, 37-amino acid peptide hormone that is released from the gut after ingestion of a meal, activating both the GLP-1 and glucagon receptors, prompting reduced food intake as well as an increase in energy expenditure, potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists. Each of DA-1241 and DA-1726 is being developed for the treatment of nonalcoholic steatohepatitis.
Directors
- Andrew Koven NEC (63)
- Gil Price PRE
- Akash Bakshi COO (32)
- Andrew Bartynski SVP
- Nadja Mannowetz SVP
- jeong Gu Kang DRC (49)
- Na Yeon Kim DRC (44)
- Jason Groves IND (50)
- Hyung Kim IND
- Michael Salsbury IND (71)
- D. Gordon Strickland IND (75)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 30th, 2014
- Public Since
- August 5th, 2016
- No. of Shareholders
- 52
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 4,906,032
- Address
- 545 Concord Avenue, Suite 210, CAMBRIDGE, 02138
- Web
- https://www.neurobopharma.com/
- Phone
- +1 8577029600
- Contact
- Michael Miller
- Auditors
- BDO USA, P.C.
Upcoming Events for NRBO
Neurobo Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Neurobo Pharmaceuticals Inc Earnings Release
Similar to NRBO
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Neurobo Pharmaceuticals share price?
As of Today at 19:15 UTC, shares in Neurobo Pharmaceuticals are trading at $3.61. This share price information is delayed by 15 minutes.
How has the Neurobo Pharmaceuticals share price performed this year?
Shares in Neurobo Pharmaceuticals last closed at $3.61 and the price had moved by -37.9% over the past 365 days. In terms of relative price strength the Neurobo Pharmaceuticals share price has underperformed the S&P500 Index by -49.85% over the past year.
What are the analyst and broker recommendations for Neurobo Pharmaceuticals?
The overall consensus recommendation for Neurobo Pharmaceuticals is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Neurobo Pharmaceuticals dividend yield?
Neurobo Pharmaceuticals does not currently pay a dividend.
Does Neurobo Pharmaceuticals pay a dividend?
Neurobo Pharmaceuticals does not currently pay a dividend.
When does Neurobo Pharmaceuticals next pay dividends?
Neurobo Pharmaceuticals does not currently pay a dividend.
How do I buy Neurobo Pharmaceuticals shares?
To buy shares in Neurobo Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Neurobo Pharmaceuticals?
As of the previous close price of $3.61, shares in Neurobo Pharmaceuticals had a market capitalisation of $17.71m.
Where are Neurobo Pharmaceuticals shares listed?
Here are the trading details for Neurobo Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NRBO
What kind of share is Neurobo Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Neurobo Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Neurobo Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Neurobo Pharmaceuticals is $36.50. That is 911.08% above the last closing price of $3.61.
Analysts covering Neurobo Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$3.00 for the next financial year.
What is the trend in the Neurobo Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neurobo Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -19.23%.
As of the last closing price of $3.61, shares in Neurobo Pharmaceuticals were trading -9.96% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Neurobo Pharmaceuticals PE Ratio?
The Neurobo Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Neurobo Pharmaceuticals?
Neurobo Pharmaceuticals' management team is headed by:
- Andrew Koven - NEC
- Gil Price - PRE
- Akash Bakshi - COO
- Andrew Bartynski - SVP
- Nadja Mannowetz - SVP
- jeong Gu Kang - DRC
- Na Yeon Kim - DRC
- Jason Groves - IND
- Hyung Kim - IND
- Michael Salsbury - IND
- D. Gordon Strickland - IND